CN110117325B - Pig CD127 polypeptide and encoding gene and application thereof - Google Patents
Pig CD127 polypeptide and encoding gene and application thereof Download PDFInfo
- Publication number
- CN110117325B CN110117325B CN201910120128.4A CN201910120128A CN110117325B CN 110117325 B CN110117325 B CN 110117325B CN 201910120128 A CN201910120128 A CN 201910120128A CN 110117325 B CN110117325 B CN 110117325B
- Authority
- CN
- China
- Prior art keywords
- pig
- antibody
- protein
- polypeptide
- porcine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 17
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 title claims description 31
- 239000012634 fragment Substances 0.000 claims abstract description 19
- 239000013598 vector Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000005847 immunogenicity Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 34
- 238000001514 detection method Methods 0.000 abstract description 25
- 210000003289 regulatory T cell Anatomy 0.000 abstract description 16
- 238000000684 flow cytometry Methods 0.000 abstract description 12
- 210000004698 lymphocyte Anatomy 0.000 abstract description 8
- 210000000207 lymphocyte subset Anatomy 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 241000282887 Suidae Species 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 3
- 208000035240 Disease Resistance Diseases 0.000 abstract description 2
- 230000007969 cellular immunity Effects 0.000 abstract description 2
- 230000002163 immunogen Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 13
- 238000002372 labelling Methods 0.000 description 12
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002649 immunization Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000009465 prokaryotic expression Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GFBLJMHGHAXGNY-ZLUOBGJFSA-N Ala-Asn-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O GFBLJMHGHAXGNY-ZLUOBGJFSA-N 0.000 description 1
- NJPMYXWVWQWCSR-ACZMJKKPSA-N Ala-Glu-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NJPMYXWVWQWCSR-ACZMJKKPSA-N 0.000 description 1
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- ORXCYAFUCSTQGY-FXQIFTODSA-N Asn-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N)N ORXCYAFUCSTQGY-FXQIFTODSA-N 0.000 description 1
- DJIMLSXHXKWADV-CIUDSAMLSA-N Asn-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O DJIMLSXHXKWADV-CIUDSAMLSA-N 0.000 description 1
- ORJQQZIXTOYGGH-SRVKXCTJSA-N Asn-Lys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ORJQQZIXTOYGGH-SRVKXCTJSA-N 0.000 description 1
- QYRMBFWDSFGSFC-OLHMAJIHSA-N Asn-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QYRMBFWDSFGSFC-OLHMAJIHSA-N 0.000 description 1
- NAPNAGZWHQHZLG-ZLUOBGJFSA-N Asp-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N NAPNAGZWHQHZLG-ZLUOBGJFSA-N 0.000 description 1
- LKIYSIYBKYLKPU-BIIVOSGPSA-N Asp-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O LKIYSIYBKYLKPU-BIIVOSGPSA-N 0.000 description 1
- GBSUGIXJAAKZOW-GMOBBJLQSA-N Asp-Ile-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GBSUGIXJAAKZOW-GMOBBJLQSA-N 0.000 description 1
- CYCKJEFVFNRWEZ-UGYAYLCHSA-N Asp-Ile-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O CYCKJEFVFNRWEZ-UGYAYLCHSA-N 0.000 description 1
- KFAFUJMGHVVYRC-DCAQKATOSA-N Asp-Leu-Met Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O KFAFUJMGHVVYRC-DCAQKATOSA-N 0.000 description 1
- BOXNGMVEVOGXOJ-UBHSHLNASA-N Asp-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N BOXNGMVEVOGXOJ-UBHSHLNASA-N 0.000 description 1
- PLOKOIJSGCISHE-BYULHYEWSA-N Asp-Val-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PLOKOIJSGCISHE-BYULHYEWSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- NLCZGISONIGRQP-DCAQKATOSA-N Cys-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N NLCZGISONIGRQP-DCAQKATOSA-N 0.000 description 1
- SRIRHERUAMYIOQ-CIUDSAMLSA-N Cys-Leu-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SRIRHERUAMYIOQ-CIUDSAMLSA-N 0.000 description 1
- HJXSYJVCMUOUNY-SRVKXCTJSA-N Cys-Ser-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N HJXSYJVCMUOUNY-SRVKXCTJSA-N 0.000 description 1
- YQEHNIKPAOPBNH-DCAQKATOSA-N Cys-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N YQEHNIKPAOPBNH-DCAQKATOSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- PXAFHUATEHLECW-GUBZILKMSA-N Gln-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N PXAFHUATEHLECW-GUBZILKMSA-N 0.000 description 1
- IRDASPPCLZIERZ-XHNCKOQMSA-N Glu-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N IRDASPPCLZIERZ-XHNCKOQMSA-N 0.000 description 1
- YKLNMGJYMNPBCP-ACZMJKKPSA-N Glu-Asn-Asp Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YKLNMGJYMNPBCP-ACZMJKKPSA-N 0.000 description 1
- SWRVAQHFBRZVNX-GUBZILKMSA-N Glu-Lys-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SWRVAQHFBRZVNX-GUBZILKMSA-N 0.000 description 1
- JDUKCSSHWNIQQZ-IHRRRGAJSA-N Glu-Phe-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JDUKCSSHWNIQQZ-IHRRRGAJSA-N 0.000 description 1
- UDEPRBFQTWGLCW-CIUDSAMLSA-N Glu-Pro-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O UDEPRBFQTWGLCW-CIUDSAMLSA-N 0.000 description 1
- KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 1
- YPHPEHMXOYTEQG-LAEOZQHASA-N Glu-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O YPHPEHMXOYTEQG-LAEOZQHASA-N 0.000 description 1
- RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 description 1
- JSNNHGHYGYMVCK-XVKPBYJWSA-N Gly-Glu-Val Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O JSNNHGHYGYMVCK-XVKPBYJWSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- HJARVELKOSZUEW-YUMQZZPRSA-N Gly-Pro-Gln Chemical compound [H]NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJARVELKOSZUEW-YUMQZZPRSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- AYUOWUNWZGTNKB-ULQDDVLXSA-N His-Phe-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AYUOWUNWZGTNKB-ULQDDVLXSA-N 0.000 description 1
- PFTFEWHJSAXGED-ZKWXMUAHSA-N Ile-Cys-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N PFTFEWHJSAXGED-ZKWXMUAHSA-N 0.000 description 1
- KFVUBLZRFSVDGO-BYULHYEWSA-N Ile-Gly-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O KFVUBLZRFSVDGO-BYULHYEWSA-N 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- VPKIQULSKFVCSM-SRVKXCTJSA-N Leu-Gln-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPKIQULSKFVCSM-SRVKXCTJSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- HGZHSNBZDOLMLH-DCAQKATOSA-N Lys-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N HGZHSNBZDOLMLH-DCAQKATOSA-N 0.000 description 1
- ONPDTSFZAIWMDI-AVGNSLFASA-N Lys-Leu-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ONPDTSFZAIWMDI-AVGNSLFASA-N 0.000 description 1
- LNMKRJJLEFASGA-BZSNNMDCSA-N Lys-Phe-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LNMKRJJLEFASGA-BZSNNMDCSA-N 0.000 description 1
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- OHXUUQDOBQKSNB-AVGNSLFASA-N Lys-Val-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OHXUUQDOBQKSNB-AVGNSLFASA-N 0.000 description 1
- HOZNVKDCKZPRER-XUXIUFHCSA-N Met-Lys-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HOZNVKDCKZPRER-XUXIUFHCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- HTKNPQZCMLBOTQ-XVSYOHENSA-N Phe-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N)O HTKNPQZCMLBOTQ-XVSYOHENSA-N 0.000 description 1
- FIRWJEJVFFGXSH-RYUDHWBXSA-N Phe-Glu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FIRWJEJVFFGXSH-RYUDHWBXSA-N 0.000 description 1
- WDOCBGZHAQQIBL-IHPCNDPISA-N Phe-Trp-Ser Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 WDOCBGZHAQQIBL-IHPCNDPISA-N 0.000 description 1
- UEHYFUCOGHWASA-HJGDQZAQSA-N Pro-Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 UEHYFUCOGHWASA-HJGDQZAQSA-N 0.000 description 1
- QKDIHFHGHBYTKB-IHRRRGAJSA-N Pro-Ser-Phe Chemical compound N([C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1 QKDIHFHGHBYTKB-IHRRRGAJSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- WKLJLEXEENIYQE-SRVKXCTJSA-N Ser-Cys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WKLJLEXEENIYQE-SRVKXCTJSA-N 0.000 description 1
- OJPHFSOMBZKQKQ-GUBZILKMSA-N Ser-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO OJPHFSOMBZKQKQ-GUBZILKMSA-N 0.000 description 1
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
- CICQXRWZNVXFCU-SRVKXCTJSA-N Ser-His-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O CICQXRWZNVXFCU-SRVKXCTJSA-N 0.000 description 1
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 description 1
- LRWBCWGEUCKDTN-BJDJZHNGSA-N Ser-Lys-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LRWBCWGEUCKDTN-BJDJZHNGSA-N 0.000 description 1
- QNBVFKZSSRYNFX-CUJWVEQBSA-N Ser-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N)O QNBVFKZSSRYNFX-CUJWVEQBSA-N 0.000 description 1
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 1
- KCZGSXPFPNKGLE-WDSOQIARSA-N Trp-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N KCZGSXPFPNKGLE-WDSOQIARSA-N 0.000 description 1
- HKIUVWMZYFBIHG-KKUMJFAQSA-N Tyr-Arg-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O HKIUVWMZYFBIHG-KKUMJFAQSA-N 0.000 description 1
- IMXAAEFAIBRCQF-SIUGBPQLSA-N Tyr-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N IMXAAEFAIBRCQF-SIUGBPQLSA-N 0.000 description 1
- FASACHWGQBNSRO-ZEWNOJEFSA-N Tyr-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FASACHWGQBNSRO-ZEWNOJEFSA-N 0.000 description 1
- HRHYJNLMIJWGLF-BZSNNMDCSA-N Tyr-Ser-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 HRHYJNLMIJWGLF-BZSNNMDCSA-N 0.000 description 1
- GOPQNCQSXBJAII-ULQDDVLXSA-N Tyr-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N GOPQNCQSXBJAII-ULQDDVLXSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- QRVPEKJBBRYISE-XUXIUFHCSA-N Val-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N QRVPEKJBBRYISE-XUXIUFHCSA-N 0.000 description 1
- CXWJFWAZIVWBOS-XQQFMLRXSA-N Val-Lys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CXWJFWAZIVWBOS-XQQFMLRXSA-N 0.000 description 1
- YLBNZCJFSVJDRJ-KJEVXHAQSA-N Val-Thr-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O YLBNZCJFSVJDRJ-KJEVXHAQSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 1
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108700004896 tripeptide FEG Proteins 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention provides a porcine CD127 polypeptide which is an extracellular portion fragment of porcine CD127 protein. The polypeptide is used as an immunogen, and in the monoclonal antibody screening process, the Elisa and the flow cytometry detection are combined to prepare a monoclonal antibody which is used for pig CD127 genes and can be used for the flow cytometry detection. By using the antibody, the detection and the typing of the lymphocyte subpopulation of the pig, particularly Treg cells, can be performed by a flow cytometer under the condition of maintaining the cell activity. In order to deeply study the functions of the porcine lymphocytes, the research and the application of cell immunity are carried out in pigs, and the further research on the relation between the disease resistance of the pigs and the lymphocytes has important practical significance.
Description
Technical Field
The invention relates to the field of molecular biology, in particular to a monoclonal antibody of a pig CD127 gene and a preparation method thereof.
Background
CD127 (leukocyte differentiation antigen molecule 127) is an important regulator IL-7 for maintaining peripheral mature T cell homeostasis, responds to the alpha chain of receptor on T lymphocytes, and is an important marker gene for lymphocyte subpopulations, especially Treg (regulatory T lymphocytes) detection and typing. anti-CD 127 flow monoclonal antibodies are an important tool antibody for studying lymphocyte subsets using flow cytometry. Currently, only commercial CD127 streaming antibodies against mice and humans are available on the market, and no CD127 streaming monoclonal antibodies against pigs are available.
Regulatory T cells (tregs) are a subpopulation of T cells with immunoregulatory function among T lymphocytes, and play an important role in maintaining autoimmune tolerance and regulating adaptive immune responses. Treg cells generally have the properties of cd4+cd25+foxp3+, in particular FoxP3 protein, one of the fork-head transcription factor family members, is considered as the marker of the most specific Treg cells. However, foxp3 is an intracellular protein, and is expressed in cells, and it is necessary to fix and perforate the cells during labelling, so that detection and sorting of Treg cells by Foxp3 cannot be performed while maintaining cell activity. It was found that intracellular FoxP3 was inversely correlated with extracellular CD127 expression in Treg cells. Further studies have shown that the promoter of CD127 has a binding site for FoxP3, and that FoxP3, upon expression, binds to the promoter region of CD127, resulting in down-regulation of the expression level of CD127, and thus Treg cells also have the characteristics of CD127 low. By taking advantage of this property, researchers often use the Treg cell surface marker CD127 for detection and analysis when detecting and isolating Treg cells. T cells are defined as Treg cells when they have the characteristics cd4+cd25+cd127 low. The Treg cells obtained by detection and separation by utilizing the characteristics can keep the integrity and the activity of the cells, and can be subjected to further culture and biological function detection. Thus CD127 antibodies are critical for T lymphocyte typing, especially Treg cell typing.
Flow cytometry detection and typing have become an important tool in immunological research. The specificity requirement for the antibody is high when the flow cytometry is used for detecting and parting lymphocyte subpopulations. The CD127 antibodies currently on the market against human and mouse are not universal between species, nor are there currently streaming monoclonal antibodies against the porcine CD127 gene. Due to the lack of antibodies, the typing and detection of lymphocyte subpopulations such as tregs of pigs is not possible.
The invention aims to provide a monoclonal antibody for pigs, which has high specificity and high sensitivity, is suitable for flow cytometry detection, and can be used for Elisa detection and immunoblotting detection.
Disclosure of Invention
In order to achieve the aim, the invention obtains extracellular fragment information of the pig CD127 gene protein through analysis, clones to obtain cDNA fragments corresponding to the genes, prokaryotic expresses corresponding gene protein peptide fragments, further purifies to obtain recombinant protein of pig CD127, then utilizes the obtained recombinant protein to immunize Balb/c mice, fuses spleen cells of the immunized mice with SP2/0 myeloma cells, combines Elisa detection and screens by a flow cytometer to obtain subcloned antibodies of flow detection.
In order to realize the technical scheme, the invention adopts the following technical means.
The invention provides a polypeptide coded by a pig CD127 gene, wherein the sequence of the polypeptide comprises a sequence shown as SEQ ID NO. 1.
Preferably, the polypeptide sequence is shown as SEQ ID NO. 1.
The invention further provides a pig CD127 gene fragment, which codes for the polypeptide.
Preferably, the sequence of the gene fragment is shown as SEQ ID NO. 2.
The present invention provides a vector comprising the above gene fragment.
The present invention provides primer pairs for amplifying the above gene fragments.
Preferably, the sequences of the primer pairs are shown in SEQ ID NO. 3-4.
The invention further provides application of the polypeptide, the gene fragment, the vector and the primer pair in preparation of the pig CD127 antibody.
The invention further discloses an antibody, which binds to the polypeptide. Specifically, it is composed of
The polypeptide is prepared by immunizing animals as an immunogen.
Preferably, the antibody is a monoclonal antibody, a humanized antibody, a polyclonal antibody. The invention screens out a hybridoma cell strain with excellent comprehensive properties and obvious secreted antibody grouping to resist pig CD127-2F8 in the preparation process of monoclonal antibodies, and the hybridoma cells are preserved in China Center for Type Culture Collection (CCTCC) NO: C2018162.
the invention discloses application of the antibody in a flow cytometer.
The invention selects extracellular fragments of pig CD127 protein as antigens, combines Elisa with flow cytometry detection in the process of monoclonal antibody screening, and prepares monoclonal antibodies which are used for pig CD127 genes and can be used for flow cytometry detection. By using the antibody, the detection and the typing of the lymphocyte subpopulation of the pig, particularly Treg cells, can be performed by a flow cytometer under the condition of maintaining the cell activity. The method can be used for analyzing the lymphocyte subpopulation of the pig by a flow cytometer, and has important practical significance for further researching the relationship between the disease resistance of the pig and the lymphocyte in order to deeply research the function of the lymphocyte of the pig and develop the research and application of cell immunity in the pig.
Drawings
Fig. 1 bioinformatics analysis of pig CD 127.
FIG. 1A is a signal peptide prediction.
FIG. 1B is a transmembrane region analysis.
FIG. 2 prokaryotic expression and purification of porcine CD127 protein.
FIG. 2A is a prokaryotic expression gel profile in which M-way protein MARKER, 1-way Pet28a induction, 2-way Pet28a no induction control, 3-way Pet32A induction bacteria, and 4-way Pet32A no induction control.
FIG. 2B shows a gel profile of protein purification, wherein M lanes of protein MARKER,1, 2 lanes of pre-protein sample loading, and 3, 4, 5, 6 lanes of imidazole elution samples are 10mM, 50mM, 100mM, and 500mM, respectively.
FIG. 3 six mice (M-M6) serum, CD3+ co-labeled flow assay (C is normal mouse serum control)
FIG. 4 mix pool M2, M4 media supernatant with CD3+ cell co-labeling assay.
FIG. 5 Co-labelling detection of secreted antibodies with porcine CD3+ in the supernatant of each subclone medium (C as control).
FIG. 6 subclone 1D8,2F3,2F8,3C6 secreted antibody Western Blot detection (T thymus-like, M-muscle protein-like).
Detailed Description
Hybridoma cell strain anti-pig CD127-2F8, this hybridoma cell has been preserved in China center for type culture collection (address: university of Wuhan, china) in 7 months 10, collection number CCTCC NO: C2018162.
the following description of the present invention refers to the accompanying drawings and examples, but is not limited to the same, and modifications and equivalents of the present invention can be made without departing from the spirit and scope of the present invention.
1) The invention firstly refers to cDNA and corresponding protein sequence of pig CD127 gene on GenBank. And then analyzing and obtaining information such as a signal peptide transmembrane domain of the gene protein by using an analysis platform such as SignalP 4.1 server,TMHMM Server and the like. Finally obtaining the extracellular fragment of the pig CD127 gene protein.
2) Based on the extracellular fragment of the gene sequence, a primer is designed and synthesized to amplify cDNA sequence corresponding to the extracellular sequence of the gene protein by PCR. And then connecting the amplified DNA sequence into a T vector, converting, enzyme cutting, then, adding the DNA sequence into an expression vector, and obtaining the recombinant protein of the pig CD127 through converting and IPTG induction expression. And then purifying by using an NI affinity chromatographic column to obtain the purified recombinant protein.
3) Mice were immunized intraperitoneally with purified protein. Mouse antisera were taken. Antibody titers of antisera were measured using Elisa. And simultaneously, the co-labeling condition of the flow cytometry antiserum and the porcine CD3 antibody on lymphocytes in the porcine blood is utilized. The method comprises the steps of selecting mouse spleen cells with higher co-labeling ratio for preparing monoclonal antibodies to carry out cell PEG fusion with SP2/0 myeloma cells, and taking cell culture supernatant to continuously detect the secretory antibody titer and the public labeling condition of the monoclonal antibodies with CD3 antibodies.
4) And selecting the subcloned cell strains from the fusion cell strains with high co-labeling ratio. And simultaneously, continuously combining Elisa with a flow cytometer for detection until the content of the antibody is stable, and obtaining a stable subclone cell strain. Finally, the monoclonal antibody of the pig CD127 gene which is applicable to the detection of the flow cytometry is selected.
Example 1 acquisition of porcine CD127 extracellular fragment recombinant protein
The cDNA sequence (NM-001146128.2) and the protein sequence (NP-001139600.1) of the pig CD127 gene on GenBank are used. The sequence was analyzed with a SignalP 4.1 server and protein signal peptides were predicted. The transmembrane domain was predicted using TMHMM Server v.2.0 (http:// www.cbs.dtu.dk/services/TMHMM /). And obtaining the extracellular fragments of the porcine CD127 gene protein 22-240. Analysis showed that the full length of the pig CD127cDNA was 1999bp, wherein the coding region (ORF) was from 49bp to 1428bp, encoding a 459aa protein. The signal peptide was predicted to show that the first 21aa of CD127 protein is the signal peptide (fig. 1A). The mature CD127 protein is 438aa, has a molecular weight of 49kD, and has an isoelectric point (pI) of 6.52. The transmembrane region showed that 220-242 of the mature peptide was the transmembrane region, N-terminal 1-219 was the extracellular region, and C-terminal 242-459 was the intracellular region (FIG. 1B).
Primers P1:5'-GGATCCAGTGGCTATGCAGAGAATGGAG-3', P2:5'-CTCGAGTCAAGGATCCACCTCCCCTGTG-3' were designed and synthesized based on the extracellular fragment of the gene sequence. The pig thymus cRNA is used as a template, and cDNA sequences corresponding to 219 amino acids in the 22 th to 240 th (namely 1 st to 219 th mature peptides) of the gene protein sequences are amplified by PCR. PCR reaction 50.0. Mu.L: 25 mu L F and Fast long PCR Mater Mix, 1 mu l of each primer, 22 mu l of ddH2O,1 mu l of cDNA template. The reaction procedure: pre-denaturation at 94℃for 2min; 15s at 94 ℃, 15s at 55 ℃ and 1min at 72 ℃ for 35 cycles; extending at 72℃for 10min. After the size of the PCR product is verified to be correct by agarose gel electrophoresis, cutting the gel, and recycling the gel by a gel recycling kit for standby.
And (3) connecting the amplified cDNA sequence corresponding to 219aa total peptide fragments of the porcine CD127 protein 22-240 into a T-Vector pMDTM 19 Vector through TA cloning, and transforming DH5 alpha competence. The positive clones were identified by PCR, inoculated with the extracted plasmid, cut with BamHI and XhoI, ligated into the double digested pET28a and pET32a vectors and transferred into the competence of the expression strain DL21 (DE 3). After the sequence of the prepared monoclonal is correct through sequencing identification, inoculating the monoclonal strain into LB liquid medium (100 mug/mL AMP), and shake culturing at 37 ℃ overnight; the next day 5mL of the culture broth was transferred to 500mL of LB liquid medium (100. Mu.g/mL AMP), cultured with shaking at 37℃for 3 hours, and induced to express by adding IPTG at a final concentration of 0.5 mM. And collecting thalli for ultrasonic crushing, centrifuging, collecting thalli supernatant and precipitate respectively, and performing SDS-PAGE analysis to obtain fusion expression proteins with the sizes between 43kD and 34kD, wherein recombinant proteins of two clone bacteria are mainly expressed in the form of inclusion bodies, and the expression quantity of pET28a vectors is large (figure 2A). The inclusion body of the protein expressed by pET28a is dissolved by 8M urea solution and then purified by an NI affinity chromatography column, and the pig CD127 recombinant protein with higher purity is obtained after imidazole elution (figure 2B).
EXAMPLE 2 mouse immunization with recombinant CD127 protein
After the recombinant protein of the CD127 extracellular fragment obtained by purification was completely emulsified with complete fries adjuvant, intraperitoneal immunization was performed with 100 μg of CD127 protein per mouse. After primary immunization, CD127 proteins emulsified with incomplete freund's adjuvant at 7, 14 and 28d, respectively, were each continued for 1 time; after 3 days of final 1 immunization, mouse serum was taken, and after prokaryotic expression of CD127 protein was coated, the antibody titer of mouse serum was detected by Elisa. The results showed that the titers of antibodies to recombinant proteins in the sera of 6 mice were all greater than 1:8000 (Table 1). And simultaneously, detecting the co-labeling condition of the mouse antiserum and the pig CD3 antibody on lymphocytes in pig blood by using a flow cytometer.
Table 1: antibody titre of 6 mice serum
The flow cytometer detection flow is as follows: pig EDTA anticoagulation 100 μl was taken, lysed by adding erythrocyte lysate, centrifuged at 800g for 5min, the supernatant was discarded, and the cell pellet was resuspended in 100 μl PBS and added with 10 μl of self-made primary antibody. After incubation at 37 ℃ for 30min, washing 3 times with PBS, AF 488-labeled goat anti-mouse IgG was added. After incubation at 37℃for 30min, the cells were resuspended in 100. Mu.L of PBS and then 1. Mu.L of CD3 antibody (BD, USA) was added, after incubation at 37℃for 10min, after 3 washes with PBS, the co-labelling of CD3 with the self-made CD127 antibody was detected by flow cytometry. The results showed that polyclonal antibodies in the serum of 6 mice were able to co-label CD3 positive cells in porcine lymphocytes. Wherein the sera of both M2 and M4 mice were able to cluster more clearly in the co-labelling of CD3 positive cells (FIG. 3).
EXAMPLE 3 monoclonal antibody screening
Mixing spleen cells of mice M2 and M4 with SP2/0 myeloma cells according to the proportion of 1:10, centrifuging 1000g for 3min, discarding supernatant, vibrating the cells to be completely and uniformly mixed, adding 1mL of preheated PEG into a water bath kettle at 37 ℃, standing for 45s, adding 10mL of RPMI1640 culture medium to stop reaction, centrifuging 1000g for 10min, discarding supernatant, adding HAT culture medium containing 20% serum, culturing for 48h at 37 ℃ in a cell culture bottle, and taking culture medium supernatant Elisa of the mixed culture cells to detect, wherein the result shows that the two mixed pool cells can secrete antibodies against pig CD 127. The primary Elisa detection OD of the M2, M4 mixed pool culture medium supernatant was 2.813,2.713 (negative control 0.088,0.079). Simultaneously, culture medium supernatant 1:100 dilution, as anti-CD 127 antibody, using flow cytometry to detect cell cd3+ cell co-labeling, showed that 2.3% of cd3+ positive cells were able to co-label with secreted antibody in M2 mix pool medium supernatant, while 67% of cd3+ cells were able to co-label with secreted antibody in M4 mix pool medium supernatant, and the clustering was clear (fig. 4).
And (3) taking M4 mixed pool cells, uniformly mixing, performing dispersion culture in a 96-well plate, screening and culturing for 10d, coating by using purified CD127, and detecting the content of secreted antibodies in the supernatant in a culture medium by using Elisa. And taking the cell strain with higher secretion of the antibody for subsequent screening until the content of the antibody is stable, and obtaining a stable subclone cell strain. A total of 6 subcloned cell lines with stable Elisa titers were obtained as 1E2,1D8,2F3,2F8,3C6,4E1. Using these subclone culture supernatants as CD127 antibodies to detect co-labelling of CD3+ cells in porcine lymphocytes, the results showed that: each subclone can label a portion of the cd3+ cells. Wherein the marked cd3+ cells of the four 1D8,2F3,2F8,3C6 subclones are more, the subclones 2F8 are more significantly clustered (fig. 5), and the hybridoma cells are preserved in the China center for type culture collection (cctccc) NO: C2018162.
example 4 validation of porcine CD127 antibodies
To verify the effectiveness of the subcloned cell lines in secreting antibodies, long white pig thymus tissue samples and muscle tissue samples were taken, homogenized after adding RIPA Buffer, 12000g, centrifuged at 4℃to take the supernatant, added protein Loading Buffer, incubated at 96℃for 10min, and separated by electrophoresis on a 12% SDS-PAGE gel. After electrophoresis, transferring the membrane, taking subcloned strain cells (1D8,2F3,2F8,3C6) with better flow detection and grouping, using culture supernatant as self-made CD127 primary antibody, using HRP-marked goat anti-mouse IgG as secondary antibody, and detecting antibody marking condition by western Blot. Western blotting procedure was as follows: the PVDF film treated by the methanol is stuck to SDS-PAGE gel, and then the two sides are soaked with electrotransfer liquid filter paper to form a sandwich structure, and 100V electrotransfer is carried out for 1.5h. The transferred film was blocked with 5% nonfat dry milk for 3min, washed 3 times with TBST wash for 10min each, and diluted CD127 antibody was added overnight at 4 ℃. TBST was washed 3 times and secondary antibody (1:500 dilution) was incubated for 1h. After washing 3 times with TBST, the color was developed by ECL color development. Scanning imaging with an LI-Cor chemiluminescent imager and analyzing the electrophoretic band size. The antibodies secreted by each subclone were detected as a single protein band of approximately 50kDa in both thymus and muscle samples, and the protein was expressed in the thymus samples in a higher amount than in the muscle samples (FIG. 6). This experiment further demonstrates the effectiveness of this antibody against porcine CD 127.
The above-described embodiment is only a preferred embodiment of the present invention, and is not limited in any way, and other variations and modifications may be made without departing from the technical aspects set forth in the claims.
Sequence listing
<110> Chongqing city, stock raising academy of sciences; chongqing market pig industry technology institute of technology
<120> a pig CD127 polypeptide, its coding gene and application
<130> 2018
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 219
<212> PRT
<213> pig
<400> 1
Ser Gly Tyr Ala Glu Asn Gly Asp Phe Asp Asp Ala Glu Pro Asp Asp
1 5 10 15
Tyr Ser Phe Ser Cys Tyr Ser Gln Leu Glu Val Asp Gly Pro Gln His
20 25 30
Leu Leu Thr Cys Ser Phe Asp Asp Pro Asp Val Asn Ser Thr His Leu
35 40 45
Glu Phe Glu Ile Cys Gly Gly Leu Leu Asp Ile Asn Cys Leu Ser Phe
50 55 60
Asn Lys Leu Gln Glu Met Tyr Phe Ile Lys Thr Lys Lys Phe Leu Leu
65 70 75 80
Ile Gly Asp Ser Lys Ile Cys Val Lys Leu Gly Gly Lys Asn Met Thr
85 90 95
Cys Arg Lys Met Lys Ile Val Lys Ile Val Lys Pro Glu Ala Pro Phe
100 105 110
Asp Ile Arg Val Thr Tyr Arg Glu Gly Ala Asn Asp Phe Val Val Thr
115 120 125
Phe Asn Thr Ser His Leu Arg Lys Lys Tyr Val Lys Asp Leu Met His
130 135 140
Glu Val Ala Tyr Arg Gln Glu Lys Asn Glu Asn Asp Trp Met His Val
145 150 155 160
Asn Leu Ser Ser Thr Lys Leu Thr Leu Leu Gln Arg Lys Leu Gln Pro
165 170 175
Asn Ala Met Tyr Glu Ile Lys Val Arg Ser Ile Pro Asn Thr Asn Tyr
180 185 190
Phe Glu Gly Phe Trp Ser Asp Trp Ser Pro Ser Phe His Phe Arg Thr
195 200 205
Pro Glu Thr Lys Ser Thr Gly Glu Val Asp Pro
210 215
<210> 2
<211> 657
<212> DNA
<213> pig
<400> 2
agtggctatg cagagaatgg agactttgac gacgcagagc cggacgacta ctccttctcg 60
tgctacagtc agctggaagt ggatggacct cagcacttgc tgacctgctc atttgatgac 120
ccggatgtca acagcaccca tctggaattt gaaatatgtg ggggcctttt ggacataaat 180
tgcctgagtt ttaataaact gcaagagatg tatttcatca agacaaagaa attcttactg 240
attggagaca gcaaaatatg tgtgaagctt ggaggaaaga acatgacttg cagaaaaatg 300
aaaatagtca aaatagttaa acctgaggct ccttttgaca taagagtcac ctaccgtgag 360
ggagcaaatg actttgtggt gacatttaat acatcgcact tgcgcaagaa gtatgtgaaa 420
gatttaatgc atgaggtagc ctaccgccag gaaaaaaatg aaaatgattg gatgcacgtg 480
aacttgtcca gtacaaagct gacgctccta caaagaaagc tccaacccaa tgcgatgtat 540
gagattaaag ttcggtccat ccctaacacc aactactttg aaggtttctg gagtgattgg 600
agtcccagtt tccacttcag aacgccagag accaaaagca caggggaggt ggatcct 657
<210> 3
<211> 28
<212> DNA
<213> artificial sequence
<400> 3
ggatccagtg gctatgcaga gaatggag 28
<210> 4
<211> 28
<212> DNA
<213> artificial sequence
<400> 4
ctcgagtcaa ggatccacct cccctgtg 28
Claims (5)
1. The polypeptide coded by the porcine CD127 with immunogenicity is characterized in that the sequence of the polypeptide is shown as SEQ ID NO. 1.
2. A pig CD127 gene fragment, which encodes the polypeptide of claim 1, has a sequence shown in SEQ ID NO. 2.
3. A vector comprising the gene fragment of claim 2.
4. A primer pair for amplifying the gene fragment of claim 2;
the primer pair is characterized in that the sequences of the primer pair are shown in SEQ ID NO. 3-4.
5. The use of the polypeptide of claim 1, the gene fragment of claim 2, the vector of claim 3, and the primer pair of claim 4 for the preparation of a porcine CD127 antibody.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810194615 | 2018-03-09 | ||
CN2018101946150 | 2018-03-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110117325A CN110117325A (en) | 2019-08-13 |
CN110117325B true CN110117325B (en) | 2023-06-20 |
Family
ID=67520545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910120128.4A Active CN110117325B (en) | 2018-03-09 | 2019-02-18 | Pig CD127 polypeptide and encoding gene and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110117325B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114957474B (en) * | 2022-06-04 | 2023-08-18 | 扬州大学 | Anti-porcine CD69 protein monoclonal antibody and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101157923A (en) * | 2007-09-14 | 2008-04-09 | 重庆市畜牧科学院 | DNA fragment related to pig polydactyly |
WO2008087219A1 (en) * | 2007-01-19 | 2008-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for regulating t cell activity |
CN106715471A (en) * | 2014-06-10 | 2017-05-24 | Ose免疫疗法 | Antibodies directed against cd127 |
CN107227311A (en) * | 2017-06-20 | 2017-10-03 | 广西壮族自治区兽医研究所 | Recombination porcine parvovirus like-particles and its preparation method and application |
-
2019
- 2019-02-18 CN CN201910120128.4A patent/CN110117325B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008087219A1 (en) * | 2007-01-19 | 2008-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for regulating t cell activity |
CN101157923A (en) * | 2007-09-14 | 2008-04-09 | 重庆市畜牧科学院 | DNA fragment related to pig polydactyly |
CN106715471A (en) * | 2014-06-10 | 2017-05-24 | Ose免疫疗法 | Antibodies directed against cd127 |
CN107227311A (en) * | 2017-06-20 | 2017-10-03 | 广西壮族自治区兽医研究所 | Recombination porcine parvovirus like-particles and its preparation method and application |
Non-Patent Citations (4)
Title |
---|
Hur,Y.J等.Sus scrofa interleukin 7 receptor (IL7R), mRNA.《Genbank database》.2015, * |
MOLECULAR CLONING AND EXPRESSION ANALYSISOF CD127 IN PIG;Yu Jin Hur等;《Animal Biotechnology》;20091231;第20卷;第40页摘要部分,第41页第2-3段以及图1 * |
Sus scrofa interleukin 7 receptor (IL7R), mRNA;Hur,Y.J等;《Genbank database》;20151018;Accession NO. NM_001146128 * |
猪CD127流式单克隆抗体的研制;赵久刚;《南方农业学报》;20180331;第49卷(第3期);第572页摘要部分 * |
Also Published As
Publication number | Publication date |
---|---|
CN110117325A (en) | 2019-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112442124B (en) | anti-CD 23 protein monoclonal antibody, cell line, preparation method and application thereof | |
CN113105547B (en) | anti-CD 5 protein monoclonal antibody and cell strain, preparation method and application thereof | |
CN111763256A (en) | Cloning of chicken CR2 gene, expression and purification of protein and preparation of polyclonal antibody thereof | |
CN111333709B (en) | B cell epitope polypeptide of serine protease inhibitor in trichina larval stage, hybridoma cell strain, monoclonal antibody and application | |
CN110117325B (en) | Pig CD127 polypeptide and encoding gene and application thereof | |
CN109306008A (en) | The single-chain antibody and preparation method thereof of one boar source property swine fever virus resistant | |
CN115947854B (en) | Anti-human CD40 protein monoclonal antibody, preparation method and application thereof | |
CN103289962B (en) | Mouse anti-human CD23 monoclonal antibody and hybridoma cell strain secreting monoclonal antibody | |
CN1234730C (en) | Mouse antichloromycetin monoclonal antibody and its use | |
CN102775486A (en) | Novel reagent and kit for renal injury monitoring | |
CN104558145B (en) | A kind of preparation method of myosin A recombinant proteins and polyclonal antibody | |
CN110564697B (en) | Duck MHCI molecular monoclonal antibody, preparation method and application thereof | |
CN106995801B (en) | Anti-tree shrew CD4 molecular monoclonal antibody, hybridoma cell strain secreting antibody and application | |
JP7216980B2 (en) | Monoclonal antibody that recognizes porcine CD4 | |
RU2715672C2 (en) | RECOMBINANT DNA OF pG4223 AND PLASMID DNA PQE 30-pG4223, STRAIN OF ESCHERICHIA COLI M 15-G4223 WHICH ENABLE TO OBTAIN G4223 POLYPEPTIDE SELECTIVELY BINDING IgG, AND USE THEREOF IN AFFINE CHROMATOGRAPHY TO ISOLATE IgG | |
CN107446893B (en) | Blec protein monoclonal antibody and its preparation method and application | |
Yoo et al. | Monoclonal antibodies reactive with chicken interleukin-17 | |
CN101603047A (en) | The foundation of prokaryotic expression, purifying and the detection method thereof of recombinant human kidney injury molecule 1 (KIM-1) | |
CN103450358A (en) | Swine GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) protein antibody and preparation method and application thereof | |
CN103467605A (en) | CD3 antigen and preparation method and application thereof | |
CN109265545A (en) | Anti-human C1orf109 monoclonal antibody of mouse and the preparation method and application thereof | |
CN116769019B (en) | ASFVp30 protein monoclonal antibody and application thereof | |
CN105085638A (en) | KSHV virus vIRF4 DNA binding domain and polyclonal antibody thereof, and preparation method of polyclonal antibody | |
CN104292333A (en) | Mouse anti-human PRRT2 monoclonal antibody, and preparation method and application thereof | |
CN108753734B (en) | Anti-tree shrew CD8 molecular monoclonal antibody, hybridoma cell strain secreting antibody and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |